Abstract
Epothilones are myxobacterial natural products that inhibit human cancer cell growth through the stabilization of cellular microtubules (i.e., a “taxol-like” mechanism of action). They have proven to be highly productive lead structures for anticancer drug discovery, with at least seven epothilone-type agents having entered clinical trials in humans over the last several years. SAR studies on epothilones have included a large number of fully synthetic analogs and semisynthetic derivatives. Previous reviews on the chemistry and biology of epothilones have mostly focused on analogs that were obtained by de novo chemical synthesis. In contrast, the current review provides a comprehensive overview on the chemical transformations that have been investigated for the major epothilones A and B as starting materials, and it discusses the biological activity of the resulting products. Many semisynthetic epothilone derivatives have been found to exhibit potent effects on human cancer cell growth and several of these have been advanced to the stage of clinical development. This includes the epothilone B lactam ixabepilone (Ixempra®, which has been approved by the FDA for the treatment of advanced and metastatic breast cancer.
Similar content being viewed by others
References
Lu MC (1995) Antimitotic agents. In: Foye WO (ed) Cancer chemotherapeutic agents. American Chemical Society, Washington, pp 345–368
Mekhail TM, Markman M (2002) Paclitaxel in cancer therapy. Expert Opin Pharmacother 3: 755–766. doi:10.1517/14656566.3.6.755
Obasaju C, Hudes GR (2001) Paclitaxel and docetaxel in prostate cancer. Hematol oncol Clin North Am 15: 525–545. doi:10.1016/S0889-8588(05)70230-6
Hamel E (1996) Antimitotic natural products and their interaction with tubulin. Med Res Rev 16: 207–231. doi:10.1002/chin.199628329
Rowinsky EK (1997) The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 48: 353–374. doi:10.1146/annurev.med.48.1.353
Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277: 665–667. doi:10.1038/277665a0
Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, Woods CM (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55: 2325–2333
Höfle G, Reichenbach H (2005) Epothilone, a myxobacterial metabolite with promising antitumor activity. In: Cragg GM, Kingston DGI, Newman DJ (eds) Anticancer agents from natural products. Taylor & Francis, Boca Raton, pp 413–450
Gerth K, Bedorf N, Höfle G, Irschik H, Reichenbach H (1996) Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot 49: 560–563. doi:10.1002/chin.199647256
Hardt IH, Steinmetz H, Gerth K, Sasse F, Reichenbach H, Höfle G (2001) New natural epothilones from Sorangium cellulosum, strains So ce90/B2 and So ce90/D13: isolation, structure elucidation, and SAR studies. J Nat Prod 64: 847–856. doi:10.1021/np000629f
Kowalski RJ, Giannakakou P, Hamel E (1997) Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol). J Biol Chem 272: 2534–2541. doi:10.1074/jbc.272.4.2534
Altmann K-H, Wartmann M, O’Reilly T (2000) Epothilones and related structures—a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 1470: M79–M91. doi:10.1016/S0304-419X(00)00009-3
Wolff A, Technau A, Brandner G (1997) Epothilone A induces apoptosis in neuroblastoma cells with multiple mechanisms of drug resistance. Int J Oncol 11: 123–126
Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, Poruchynsky MS (1997) Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272: 17118–17125. doi:10.1074/jbc.272.27.17118
Lechleider RJ, Kaminskas E, Jiang X, Aziz R, Bullock J, Kasliwal R, Harapanhalli R, Pope S, Sridhara R, Leighton J, Booth B, Dagher R, Justice R, Pazdur R (2008) Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies. Clin Cancer Res 14: 4378–4384. doi:10.1158/1078-0432.CCR-08-0015
Nicolaou KC, Roschangar F, Vourloumis D (1998) Chemical biology of epothilones. Angew Chem Int Ed 37: 2014–2045. doi:10.1002/(SICI)1521-3773(19980817)37:15<2014::AID-ANIE2014>3.3.CO;2-U
Harris CR, Danishefsky SJ (1999) Complex target-oriented synthesis in the drug discovery process: a case history in the dEpoB series. J Org Chem 64: 8434–8456. doi:10.1021/jo991006d
Mulzer J, Martin HJ, Berger M (1999) Progress in the synthesis of chiral heterocyclic natural products: epothilone B and tartrolon B. J Heterocycl Chem 36: 1421–1436. doi:10.1002/chin.200019288
Nicolaou KC, Ritzen A, Namoto K (2001) Recent developments in the chemistry, biology and medicine of the epothilones. Chem Commun 1523–1535. doi:10.1039/B104949F
Altmann K-H (2004) The merger of natural product synthesis and medicinal chemistry: on the chemistry and chemical biology of epothilones. Org Biomol Chem 2: 2137–2152. doi:10.1039/B405839A
Watkins EB, Chittiboyina AG, Jung JC, Avery MA (2005) The epothilones and related analogues-A review of their syntheses and anti-cancer activities. Curr Pharm Des 11: 1615–1653. doi:10.2174/1381612053764742
Watkins EB, Chittiboyina AG, Avery MA (2006) Recent developments in the syntheses of the epothilones and related analogues. Eur J Org Chem 18: 4071–4084. doi:10.1002/ejoc.200600149
Wartmann M, Altmann K-H (2002) The biology and medicinal chemistry of epothilones. Curr Med Chem Anti-Cancer Agents 2: 123–148. doi:10.2174/1568011023354489
Altmann K-H (2003) Epothilone B and its analogs—a new family of anticancer agents. Mini-Rev Med Chem 3: 149–158. doi:10.2174/1389557033405269
Borzilleri RM, Vite GD (2002) Epothilones: new tubulin polymerization agents in preclinical and clinical development. Drugs Future 27: 1149–1164. doi:10.1358/dof.2002.027.12.711728
Altmann K-H (2005) Recent developments in the chemistry and biology of epothilones. Curr Pharm Des 11: 1595–1613. doi:10.2174/1381612053764715
Altmann K-H, Pfeiffer B, Arseniyadis S, Pratt BA, Nicolaou KC (2007) The chemistry and biology of epothilones—the wheel keeps turning. ChemMedChem 2: 397–423. doi:10.1002/cmdc.200600206
Butler MS (2004) The role of natural product chemistry in drug discovery. J Nat Prod 67: 2141–2153. doi:10.1021/np040106y
Hamann MT (2003) Enhancing marine natural product structural diversity and bioactivity through semisynthesis and biocatalysis. Curr Pharm Design 9: 879–889. doi:10.2174/1381612033455297
Henkel T, Brunne RM, Müller H, Reichel F (1999) Statistical investigation into the structural complementarity of natural products and synthetic compounds. Angew Chem Int Ed 38: 643–647. doi:10.1002/(SICI)1521-3773(19990301)38:5<643::AID-ANIE643>3.0.CO;2-G
Kuhn M, Keller-Juslén C, von Wartburg A (1969) Communication on mitosis-inhibiting natural substances. 22. Partial synthesis of 4’-demethylepipodophyllotoxin. Helv Chim Acta 52: 944–947. doi:10.1002/hlca.19690520410
Keller-Juslén C, Kuhn M, Wartburg A, Stähelin H (1971) Mitosis-inhibiting natural products. 24. Synthesis and antimitotic activity of glycosidic lignan derivatives related to podophyllotoxin. J Med Chem 14: 936–940. doi:10.1021/jm00292a012
You Y (2005) Podophyllotoxin derivatives: current synthetic approaches for new anticancer agents. Curr Pharm Design 11: 1695–1717. doi:10.2174/1381612053764724
Sawada S, Yokokura T, Miyasaka T (1995) Synthesis and antitumor activity of A-ring or E-lactone modified water-soluble prodrugs of 20(S)-camptothecin, including development of irinotecan hydrochloride trihydrate (CPT-11). Curr Pharm Design 1: 113–132
Kingsbury WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, Gallagher G, Caranfa MJ, McCabe FL, Faucette L, Johnson RK, Hertzberg RP (1991) Synthesis of water-soluble (aminoalkyl) camptothecin analogs: inhibition of topoisomerase I and antitumor activity. J Med Chem 34: 98–107. doi:10.1021/jm00105a017
Mathijssen RHJ, Loos WJ, Verweij J, Sparreboom A (2002) Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets 2: 103–123. doi:10.2174/1568009023333890
Guenard D, Gueritte-Voegelein F, Potier P (1993) Taxol and taxotere: discovery, chemistry, and structure-activity relationships. Acc Chem Res 26: 160–167. doi:10.1021/ar00028a005
Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93: 2325–2327. doi:10.1021/ja00738a045
Holton RA, Biediger RJ, Boatman D (1995) Semisynthesis of taxol and taxotere. In: Suffness M (ed.) Taxol: science and applications. CRC, Boca Raton, pp 97–121. doi:10.1002/chin.199552275
Wuts PGM (1998) Semisynthesis of Taxol. Curr Opin Drug Discov Dev 1: 329–337
Vite GD, Borzilleri RM, Kim SH, Regueiro-Ren A, Humphreys WG, Lee FYF (2001) Epothilones A and B: springboards for semisynthesis of promising antimitotic agents. In: Ojima I, Vite GD, Altmann K-H (eds) Anticancer agents—frontiers in cancer chemotherapy. ACS Symposium Series 796. American Chemical Society, Washington, pp 148–170
Sefkow M, Kiffe M, Höfle G (1998) Derivatization of the C12–C13 functional groups of epothilones A, B and C. Bioorg Med Chem Lett 8: 3031–3036. doi:10.1016/S0960-894X(98)00546-0
Altmann K-H, Bold G, Caravatti G, End N, Flörsheimer A, Guagnano V, O’Reilly T, Wartmann M (2000) Epothilones and their analogs—potential new weapons in the fight against cancer. Chimia 54: 612–621
Regueiro-Ren A, Leavitt K, Kim SH, Höfle G, Kiffe M, Gougoutas JZ, DiMarco JD, Lee FYF, Fairchild CR, Long BH, Vite GD (2002) SAR and pH stability of cyano-substituted epothilones. Org Lett 4: 3815–3818. doi:10.1021/ol026589j
Regueiro-Ren A, Borzilleri RM, Zheng X, Kim SH, Johnson JA, Fairchild CR, Lee FY, Long BH, Vite GD (2001) Synthesis and biological activity of novel epothilone aziridines. Org Lett 3: 2693–2696. doi:10.1021/ol016273w
Glunz PW, He L, Horwitz SB, Chakravarty S, Ojima I, Chou TC, Danishefsky SJ (1999) The synthesis and evaluation of 12,13-benzodesoxyepothilone B: a highly convergent route. Tetrahedron Lett 40: 6895–6898. doi:10.1016/S0040-4039(99)01433-1
Sefkow M, Kiffe M, Schummer D, Höfle G (1998) Oxidative and reductive transformations of epothilone A. Bioorg Med Chem Lett 8: 3025–3030. doi:10.1016/S0960-894X(98)00545-9
Pfeiffer B, Hauenstein K, Merz P, Gertsch J, Altmann K-H (2009) Synthesis and SAR of C12–C13-oxazoline derivatives of epothilone A. Bioorg Med Chem Lett 19: 3760–3763. doi:10.1016/j.bmcl.2009.04.112
Johnson J, Kim SH, Bifano M, DiMarco J, Fairchild C, Gougoutas J, Lee F, Long B, Tokarski J, Vite GD (2000) Synthesis, structure proof, and biological activity of epothilone cyclopropanes. Org Lett 2: 1537–1540. doi:10.1021/ol0058240
Su DS, Balog A, Meng D, Bertinato P, Danishefsky SJ, Zheng YH, Chou TC, He L, Horwitz SB (1997) Structure-activity relationships of the epothilones and the first in vivo comparison with paclitaxel. Angew Chem Int Ed 36: 2093–2096. doi:10.1002/anie.199720931
Meng D, Su DS, Balog A, Bertinato P, Sorensen EJ, Danishefsky SJ, Zheng YH, Chou T-C, He L, Horwitz SB (1997) Remote effects in macrolide formation through ring-forming metathesis: an application to the synthesis of fully active epothilone congeners. J Am Chem Soc 119: 2733–2734. doi:10.1021/ja964275j
Su DS, Meng D, Bertinato P, Balog A, Sorensen EJ, Danishefsky SJ, Zheng YH, Chou T-C, He L, Horwitz SB (1997) Total synthesis of (-)-epothilone B: an extension of the Suzuki coupling method and insights into structure-activity relationships of the epothilones. Angew Chem Int Ed 36: 757–759. doi:10.1002/anie.199707571
Nicolaou KC, Winssinger N, Pastor J, Ninkovic S, Sarabia F, He Y, Vourloumis D, Yang Z, Li T, Giannakakou P, Hamel E (1997) Synthesis of epothilones A and B in solid and solution phase. Nature 387: 268–272. doi:10.1038/387268a0
Chou TC, Zhang XG, Balog A, Su DS, Meng D, Savin K, Bertino JR, Danishefsky SJ (1998) Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc Natl Acad Sci USA 95: 9642–9647. doi:10.1073/pnas.95.16.9642
Lichtner RB, Rotgeri A, Bunte T, Buchmann B, Hoffmann J, Schwede W, Skuballa W, Klar U (2001) Subcellular distribution of epothilones in human tumor cells. Proc Natl Acad Sci USA 98: 11743–11748. doi:10.1073/pnas.171023398
Buey RM, Diaz JF, Andreu JM, O’Brate A, Giannakakou P, Nicolaou KC, Sasmal PK, Ritzén A, Namoto K (2004) Interactions of epothilone analogs with the paclitaxel binding site: relationship between binding affinity, microtubule stabilization, and cytotoxicity. Chem Biol 11: 225–236. doi:10.1016/j.chembiol.2004.01.014
Niggemann J, Michaelis K, Frank R, Zander N, Höfle G (2002) Natural product-derived building blocks for combinatorial synthesis. Part 1. Fragmentation of natural products from myxobacteria. JCS Perkin Trans 1: 2490–2503. doi:10.1039/b206953a
Borzilleri RM, Zheng X, Schmidt RJ, Johnson JA, Kim SH, DiMarco JD, Fairchild CR, Gougoutas JZ, Lee FYF, Long BH, Vite GD (2000) A novel application of a Pd(0)-catalyzed nucleophilic substitution reaction to the regio- and stereoselective synthesis of lactam analogues of the epothilone natural products. J Am Chem Soc 122: 8890–8897. doi:10.1021/ja001899n
Schinzer D, Altmann K-H, Stuhlmann F, Bauer A, Wartmann M (2000) Synthesis and biological evaluation of aza-epothilones. ChemBioChem 1: 67–70. doi:10.1002/1439-7633(20000703)1:1<67::AID-CBIC67>3.0.CO;2-I
Stachel SJ, Lee CB, Spassova M, Chappell MD, Bornmann WG, Danishefsky SJ, Chou T-C, Guan Y (2001) On the interactivity of complex synthesis and tumor pharmacology in the drug discovery process: total synthesis and comparative in vivo evaluations of the 15-Aza epothilones. J Org Chem 66: 4369–4378. doi:10.1021/jo010275c
Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD, Rose WC, Kramer RA (2001) BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7: 1429–1437
Höfle G, Glaser N, Kiffe M, Hecht H-J, Sasse F, Reichenbach H (1999) N-oxidation of epothilone A-C and O-acyl rearrangement to C-19- and C21-substituted epothilones. Angew Chem Int Ed 38: 1971–1974. doi:10.1002/(SICI)1521-3773(19990712)38:13/14<1971::AID-ANIE1971>3.0.CO;2-X
Sefkow M, Höfle G (1998) Substitutions at the thiazole moiety of epothilone. Heterocycles 48: 2485–2488. doi:10.3987/COM-98-8351
Huisgen R, Kolbeck W (1965) N-Acyloxyammonium salts. Tetrahedron Lett 6: 783–787. doi:10.1016/S0040-4039(01)83985-X
Höfle G, Glaser N, Leibold T, Karama U, Sasse F, Steinmetz H (2003) Semisynthesis and degradation of the tubulin inhibitors epothilone and tubulysin. Pure Appl Chem 75: 167–178. doi:10.1351/pac200375020167
Höfle G, Glaser N, Leibold T (2000) Synthesis and cytotoxicity of C-21 modified epothilones. Ger Offen DE 19907588
Uyar D, Takigawa N, Mekhail T, Grabowski D, Markman M, Lee F, Canetta R, Peck R, Bukowski R, Ganapathi R (2003) Apoptotic pathways of epothilone BMS 310705. Gynecol Oncol 91: 173–178. doi:10.1016/S0090-8258(03)00481-5
Wartmann M, Loretan J, Reuter R, Hattenberger M, Muller M, Vaxelaire J, Maira S-M, Flörsheimer A, O’Reilly T, Nicolaou KC, Altmann K-H (2004) Preclinical pharmacological profile of ABJ879, a novel epothilone B analog with potent and protracted anti-tumor activity. Proceedings of the American Association for Cancer Research 45. Abstract #5440
http://sec.edgar-online.com/2007/01/31/0001047469-07-000510/Section5.asp
Höfle G, Glaser N, Leibold T, Sefkow M (1999) Epothilone A-D and their thiazole-modified analogs as novel anticancer agents. Pure Appl Chem 71:2019–2024. doi:10.1351./pac199971112019. See also: Glaser N (2001) Semisynthese Seitenketten-Modifizierter Epothilone. Doctoral Thesis, Technical University of Braunschweig.
Altmann K-H, Blommers MJJ, Caravatti G, Flörsheimer A, Nicolaou KC, OReilly T, Schmidt A, Schinzer D, Wartmann M (2001) Synthetic and semisynthetic analogs of epothilones: chemistry and biological activity. In: Ojima I, Vite GD, Altmann K-H (eds): Anticancer agents—frontiers in cancer chemotherapy. ACS Symposium Series 796. American Chemical Society, Washington, pp 112–130. doi:10.1021/bk-2001-0796.ch007
Karama U, Höfle G (2003) Synthesis of epothilone 16,17-alkyne analogs by replacement of the C13-C15(O)-ring segment of natural epothilone C. Eur J Org Chem: 1042–1049. doi:10.1002/ejoc.200390146
Dong SD, Sundermann K, Smith KMJ, Petryka J, Liu F, Myles DC (2004) Rapid access to epothilone analogs via semisynthetic degradation and reconstruction of epothilone D. Tetrahedron Lett 45: 1945–1947. doi:10.1016/j.tetlet.2003.12.123
Klar U, Buchmann B, Schwede W, Skuballa W, Hoffmann J, Lichtner RB (2006) Total synthesis and antitumor activity of ZK-EPO: The first fully synthetic epothilone in clinical development. Angew Chem Int Ed 45: 7942–7948. doi:10.1002/anie.200602785
Feyen F, Cachoux F, Gertsch J, Wartmann M, Altmann K-H (2008) Epothilones as Lead Structures for the Synthesis-Based Discovery of New Chemotypes for Microtubule Stabilization. Acc Chem Res 41: 21–31. doi:10.1021/ar700157x
Rivkin A, Yoshimura F, Gabarda AE, Cho YS, Chou T-C, Dong H, Danishefsky SJ (2004) Discovery of (E)-9,10-dehydroepothilones through chemical synthesis: on the emergence of 26-trifluoro-(E)-9,10-dehydro-12,13-desoxyepothilone B as a promising anticancer drug candidate. J Am Chem Soc 126:10913–10922. doi:10.1021/ja046992gx
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Altmann, KH., Gaugaz, F.Z. & Schiess, R. Diversity through semisynthesis: the chemistry and biological activity of semisynthetic epothilone derivatives. Mol Divers 15, 383–399 (2011). https://doi.org/10.1007/s11030-010-9291-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11030-010-9291-0